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Management of adverse events in patients 
with acute myeloid leukemia in remission 
receiving oral azacitidine: experience 
from the phase 3 randomized QUAZAR AML-001 
trial
Farhad Ravandi1* , Gail J. Roboz2,3, Andrew H. Wei4,5, Hartmut Döhner6, Christopher Pocock7, 
Dominik Selleslag8, Pau Montesinos9, Hamid Sayar10, Maurizio Musso11, Angela Figuera‑Alvarez12, Hana Safah13, 
William Tse14, Sang Kyun Sohn15, Devendra Hiwase16, Timothy Chevassut17, Francesca Pierdomenico18, 
Ignazia La Torre19, Barry Skikne20,21, Rochelle Bailey21, Jianhua Zhong21, C. L. Beach21 and Herve Dombret22,23 
Abstract 
Background: Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with 
intensive chemotherapy (IC) will eventually relapse and post‑relapse prognosis is dismal. In the pivotal QUAZAR AML‑
001 trial, oral azacitidine maintenance therapy significantly prolonged overall survival by 9.9 months (P < 0.001) and 
relapse‑free survival by 5.3 months (P < 0.001) compared with placebo in patients with AML in first remission after 
IC who were not candidates for transplant. Currently, the QUAZAR AML‑001 trial provides the most comprehensive 
safety information associated with oral azacitidine maintenance therapy. Reviewed here are common adverse events 
(AEs) during oral azacitidine treatment in QUAZAR AML‑001, and practical recommendations for AE management 
based on guidance from international cancer consortiums, regulatory authorities, and the authors’ clinical experience 
treating patients in the trial.
Methods: QUAZAR AML‑001 is an international, placebo‑controlled randomized phase 3 study. Patients 
aged ≥ 55 years with AML and intermediate‑ or poor‑risk cytogenetics at diagnosis, who had attained first complete 
remission (CR) or CR with incomplete blood count recovery (CRi) within 4 months before study entry, were rand‑
omized 1:1 to receive oral azacitidine 300 mg or placebo once‑daily for 14 days in repeated 28‑day cycles. Safety was 
assessed in all patients who received ≥ 1 dose of study drug.
Results: A total of 469 patients received oral azacitidine (n = 236) or placebo (n = 233). Median age was 68 years. 
Patients received a median of 12 (range 1–80) oral azacitidine treatment cycles or 6 (1–73) placebo cycles. Gastroin‑
testinal AEs were common and typically low‑grade. The most frequent grade 3–4 AEs during oral azacitidine therapy 
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Background
Acute myeloid leukemia (AML) is primarily a disease 
of older individuals; median age at diagnosis is 68 years 
[1]. About 40–60% of patients aged ≥ 60 years with AML 
attain morphologic remission (< 5% blasts in bone mar-
row [2]) with intensive chemotherapy (IC), but most of 
these patients will eventually relapse [3, 4]. Effective, 
well-tolerated maintenance therapies are needed to pro-
long remission, reduce risk of relapse, and improve sur-
vival for older patients with AML. Maintenance therapy 
for AML has been controversial historically due to lim-
ited efficacy and the potential for substantial treatment-
related toxicity [5–7]. Additionally, patients with AML 
in remission generally report improving health-related 
quality of life (HRQoL) over time [8] and may be ambiv-
alent toward receiving further active therapy that can 
induce unwanted effects [9].
Azacitidine is a DNA methyltransferase inhibitor and 
hypomethylating agent (HMA) that, when administered 
parenterally for 5–7  days per 28-day treatment cycle, 
induces clinical responses and prolongs overall survival 
(OS) as front-line treatment in older patients with AML 
or higher-risk myelodysplastic syndromes (MDS) [10, 
11]. Injectable azacitidine has been shown to prolong dis-
ease-free survival (DFS)—but not OS—as maintenance 
therapy in patients ≥ 60 years of age with AML in remis-
sion after IC [12]. Oral azacitidine (formerly CC-486) has 
been evaluated in patients with hematologic malignan-
cies in multiple clinical trials [13–19]. Oral administra-
tion allows for extended dosing schedules (> 7  days per 
cycle) to sustain the therapeutic activity of azacitidine 
across the entire treatment cycle. Importantly, the oral 
and parenteral formulations of azacitidine are not bio-
equivalent and not interchangeable [20].
Oral azacitidine is approved in the United States, Euro-
pean Union, and Canada for treatment of adult patients 
with AML in first remission after IC who are not eligi-
ble to complete intensive curative therapy (e.g., hemat-
opoietic stem cell transplant [HSCT]) [20, 21]. These 
regulatory approvals were based on results of the piv-
otal randomized, phase 3 QUAZAR AML-001 trial, 
which assessed oral azacitidine as maintenance therapy 
for patients aged ≥ 55 years with AML in first remission 
after IC (induction ± consolidation) who were not can-
didates for HSCT [22]. In that trial, treatment with oral 
azacitidine 300-mg once-daily 14  days per 28-day cycle 
was associated with significantly prolonged OS (median 
24.7 vs. 14.8 months from randomization; P < 0.001) and 
relapse-free survival (RFS) (median 10.2 vs. 4.8 months; 
P < 0.001) compared with placebo (Fig.  1) [22]. Hema-
tologic and gastrointestinal (GI) adverse events (AEs) 
were common in both treatment arms, but rates of these 
events were higher with active treatment.
GI events are among the most common AEs to occur 
during treatment with both formulations of azacitidine; 
these are typically low-grade and occur most often dur-
ing early treatment cycles [19, 23]. Because cytotoxic 
chemotherapies act on healthy myeloproliferative cells 
in addition to leukemic targets, many AML treatments, 
including HMAs, have myelosuppressive effects that may 
induce or exacerbate cytopenias [24]. These AEs could 
negatively affect patients’ HRQoL and interfere with suc-
cessful maintenance therapy, potentially leading to thera-
peutic nonadherence or treatment discontinuation [25], 
so it is important to effectively manage common AEs 
during oral azacitidine therapy.
Reported here are rates of common GI and hemato-
logic AEs and infections during oral azacitidine treat-
ment in the QUAZAR AML-001 trial, and associated 
management strategies, supportive care guidelines from 
international experts who care for patients with AML 
[26–33], and suggestions based on the authors’ clini-




Comprehensive study design, patient eligibility, and 
overall efficacy and safety outcomes for QUAZAR 
AML-001 (NCT01757535) are reported elsewhere 
[22]. Briefly, eligible patients were aged ≥ 55 years with 
newly diagnosed AML in first complete remission (CR) 
were hematologic events. AEs infrequently required permanent discontinuation of oral azacitidine (13%), suggesting 
they were effectively managed with use of concomitant medications and oral azacitidine dosing modifications.
Conclusion: Oral azacitidine maintenance had a generally favorable safety profile. Prophylaxis with antiemetic 
agents, and blood count monitoring every other week, are recommended for at least the first 2 oral azacitidine treat‑
ment cycles, and as needed thereafter. Awareness of the type, onset, and duration of common AEs, and implemen‑
tation of effective AE management, may maximize treatment adherence and optimize the survival benefits of oral 
azacitidine AML remission maintenance therapy.
Trial registration This trial is registered on clinicaltrials.gov: NCT01757535 as of December 2012.
Keywords: Oral azacitidine, CC‑486, Safety, Maintenance
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or CR with incomplete blood count recovery (CRi) 
after induction chemotherapy, with or without sub-
sequent  consolidation courses, and had intermedi-
ate- or poor-risk cytogenetics, Eastern Cooperative 
Oncology Group performance status (ECOG PS) score 
of ≤ 2, absolute neutrophil count (ANC) ≥ 0.5 ×  109/L, 
and platelet count ≥ 20 ×  109/L at screening. Within 
4  months of achieving CR/CRi, patients were ran-
domized 1:1 to receive oral azacitidine 300-mg or 
placebo once-daily for 14 days of repeated 28-day treat-
ment cycles. All patients could receive supportive care 
measures according to local practice, including (but 
not limited to) red blood cell (RBC) transfusions, plate-
let transfusions, and erythropoiesis stimulating agents 
(ESAs); antibiotic, antiviral, and antifungal therapies; 
and myeloid growth factors (e.g., granulocyte colony 
stimulating factor [G-CSF]).
Safety was assessed in all patients who received ≥ 1 
dose of study drug, per investigator reporting of treat-
ment-emergent AEs occurring between the date of first 
study drug dose through 28  days after last dose. AEs 
were defined using the Medical Dictionary for Regu-
latory Activities (MedDRA) version 22.0 and graded 
for severity using the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (NCI-
CTCAE) version 4.0. Any AE that resulted in death, 
was life-threatening, required or prolonged inpatient 
hospitalization, resulted in significant disability, or led 
to congenital anomalies or other important medical 
events was considered a serious event. Study drug dos-
ing could be interrupted, delayed, or reduced to manage 
AEs. While development of ≥ 5% bone marrow blasts is 
considered morphologic AML relapse [2], patients who 
experienced AML relapse with 5–15% blasts in blood 
Fig. 1 Kaplan–Meier analysis of overall survival and relapse‑free survival from the time of randomization. From Wei et al. [22]. Copyright © (2021) 
Massachusetts Medical Society. Reprinted with permission
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or bone marrow could have their randomized dosing 
regimen extended from 14 to 21 days/cycle at the dis-
cretion of the treating physician. Treatment discontinu-
ation was mandatory for patients with > 15% blasts. This 
report excludes MedDRA terms specifically related to 
AML relapse (e.g., high-level term “leukemia”) because 
relapse was an efficacy measure of the trial.
Results
Patients and overall safety in QUAZAR AML‑001
In all, 472 patients were randomized to treatment; the 
safety-evaluable population comprised 469 patients 
(99%) who received ≥ 1 dose of oral azacitidine 
(n = 236) or placebo (n = 233). Median age overall was 
68 years (range 55–86). In the oral azacitidine arm, 86% 
of patients had intermediate-risk cytogenetics at AML 
diagnosis, 78% had achieved CR after induction, and 
78% received ≥ 1 course of consolidation before study 
randomization. Median baseline ANC was 3.0 ×  109/L, 
hemoglobin concentration was 11.3 g/dL, platelet count 
was 154 ×  109/L, and white blood cell (WBC) count was 
4.9 ×  109/L (Table 1).
Oral azacitidine had a manageable safety profile over-
all, with no unexpected safety events. Patients received 
a median of 12 (range 1–80) oral azacitidine treat-
ment cycles or 6 (1–73) cycles of placebo [22]. In both 
treatment arms, the median cycle length was 28  days, 
median number of days treated per cycle was 14, and 
median compliance rate was 100%. AEs led to tem-
porary dosing interruptions for 43% of patients who 
received oral azacitidine and 17% of patients in the pla-
cebo arm, and required dose reductions for 16% and 3% 
of patients, respectively. AEs infrequently led to perma-
nent discontinuation of oral azacitidine (n = 31; 13%) or 
placebo (n = 10; 4%) [22].
The most common AEs in both treatment arms were 
grade 1–2 GI events (Table 2). The most frequent grade 
3–4 AEs (reported as events or indicated by laboratory 
measures) in both treatment arms were cytopenias, 
primarily neutropenia (in 41% of patients in the oral 
azacitidine arm and 24% in the placebo arm), thrombo-
cytopenia (in 22% and 21%, respectively), and anemia 
(in 14% and 13%) [22]. Serious AEs reported in ≥ 1% of 
patients are shown in Additional file 1: Table S1. Hos-
pitalization (for any cause, including AML relapse) was 
required for 46% of patients in the oral azacitidine arm 
and 51% of patients in the placebo arm. When account-
ing for different durations of exposure to study drugs, 
exposure-adjusted incidence rates of hospitalization 
and days in hospital were each significantly lower dur-
ing oral azacitidine treatment compared with placebo 
[34].
Gastrointestinal events
GI-directed prophylaxis was allowed but not manda-
tory in QUAZAR AML-001; the study protocol included 
dose-modification recommendations for grade ≥ 3 GI 
AEs (diarrhea, nausea, and vomiting). Overall, GI AEs 
occurred in 91% and 62% of patients in the oral azaciti-
dine and placebo arms, respectively. The most common 
GI events in the oral azacitidine arm were nausea (65%), 
vomiting (60%), and diarrhea (50%), and most GI events 
were low-grade (Table 3). Few patients in the oral azac-
itidine arm experienced grade-3 nausea (3%), vomiting 
(3%), or diarrhea (5%), and only 1 of these events was 
grade 4 in severity (diarrhea) at any time on-study. Seri-
ous GI events were reported for 15 patients (6%) in the 
oral azacitidine arm; the only serious events reported 
for > 1 patient were diarrhea (n = 3), gastritis (n = 2), and 
vomiting (n = 2). GI events occurred most frequently 
during the first 2 treatment cycles and decreased in inci-
dence thereafter. In cycles 1–2, 3–4, and 5–6, respec-
tively, nausea was reported in 53%, 17%, and 15% of 
patients receiving oral azacitidine; vomiting occurred in 
49%, 15%, and 10% of patients; and diarrhea occurred in 
29%, 16%, and 11% of patients (Fig. 2).
Management
GI AEs were primarily managed with standard support-
ive care measures and oral azacitidine dosing modifica-
tions. Modifications to oral azacitidine dosing for nausea, 
vomiting, and diarrhea were mainly treatment interrup-
tions (for 6%, 4%, and 4% of patients, respectively) and 
dose reductions (3%, 2%, and 1%), and these events rarely 
required treatment discontinuation (2%, 2%, and 1%). 
The use of concomitant medications for nausea, vomit-
ing, and diarrhea decreased over time in parallel with 
rates of GI AEs as therapy continued (Fig. 2). The most 
common GI-directed concomitant medications in the 
oral azacitidine arm were 5-HT3 receptor antagonists 
[ondansetron (83%), metoclopramide (34%), granisetron 
(18%)], and proton pump inhibitors [PPIs; pantoprazole 
(30%), omeprazole/esomeprazole (29%)]. Intravenous 
fluids (e.g., NaCl, electrolyte solutions, mannitol) were 
administered for approximately 10% of patients in each 
arm. Median durations of nausea, vomiting, and diarrhea 
were 10  days, 2  days, and 6  days, respectively. As men-
tioned, antiemetic prophylaxis was not mandated during 
the trial.
Oral azacitidine can be taken with or without food 
[35, 36]. At clinically relevant concentrations, oral 
azacitidine does not substantially inhibit or induce 
cytochrome P450 enzymes [20], decreasing the risk 
of adverse drug interactions, and oral azacitidine 
pharmacokinetics are not meaningfully altered by 
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Table 1 QUAZAR AML‑001 baseline characteristics (safety‑evaluable population)
Safety-evaluable patients received at least 1 dose of study drug
AML acute myeloid leukemia, ANC absolute neutrophil count, CR complete remission, CRi CR with incomplete blood count recovery, ECOG PS Eastern Cooperative 
Oncology Group performance status, MRD measurable residual disease, NCCN National Comprehensive Cancer Network, WBC white blood cells, WHO World Health 
Organization
a A patient may have had more than 1 reason for ineligibility
b Two patients in each treatment arm enrolled beyond the 4-month (± 7 days) inclusion window from the time of achieving CR/CRi (protocol violations)
c Patients may have had multiple visits between screening and randomization. All patients met relevant eligibility criteria at the screening visit
d Central assessment by flow cytometry, using a ≥ 0.1% MRD-positive threshold
Parameter Oral azacitidine (N = 236) Placebo (N = 233)
Age, years, median (range) 68 (55‒86) 68 (55‒82)
ECOG PS score, n (%)
0 116 (49.2) 111 (47.6)
1 99 (41.9) 105 (45.1)
2‒3 21 (8.9) 17 (7.3)
De novo AML, n (%) 211 (89.4) 215 (92.3)
WHO AML classification, n (%)
Not otherwise specified 147 (62.3) 144 (61.8)
Myelodysplasia‑related changes 49 (20.8) 42 (18.0)
Recurrent genetic abnormalities 38 (16.1) 46 (19.7)
Therapy‑related 2 (0.8) 0
NCCN cytogenetic risk at diagnosis, n (%)
Intermediate 202 (85.6) 202 (86.7)
Poor 34 (14.4) 31 (13.3)
Response after induction, n (%)
CR 185 (78.4) 197 (84.5)
Cri 51 (21.6) 36 (15.5)
Received consolidation, n (%)
Yes 184 (78.0) 191 (82.0)
1 cycle 110 (46.6) 101 (43.3)
2 cycles 69 (29.2) 77 (33.0)
3 cycles 5 (2.1) 13 (5.6)
No 52 (22.0) 42 (18.0)
Reason ineligible for transplanta
Age 154 (65) 152 (65)
Comorbidities 52 (22) 50 (21)
Performance status 14 (6) 9 (4)
No available donor 37 (16) 35 (15)
Patient decision 19 (8) 32 (14)
Unfavorable cytogenetics 6 (3) 10 (4)
Other 28 (12) 21 (9)
Time from induction to randomization, months, median (range) 3.9 (1.4‒8.8) 4.0 (1.3‒15.1)
Time from CR/CRi to randomization, days, median (range) 84 (7‒154b) 86 (7‒263b)
Bone marrow blasts, percent, median (range) 2.0 (0.0‒5.0) 2.0 (0.0‒6.5c)
MRD + at randomization,d n (%) 102 (43.2) 115 (49.4)
ANC,  109/L, median (range) 3.0 (0.3b‒15.9) 2.8 (0.5‒9.6)
Hemoglobin, g/dL, median (range) 11.3 (7.5‒15.9) 10.8 (7.7‒14.9)
Platelets,  109/L, median (range) 154 (22‒801) 179  (16b‒636)
WBC,  109/L, median (range) 4.9 (0.8‒18.7) 4.5 (1.3‒12.6)
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coadministration of a PPI [36]. Treatment of GI reflux 
with a PPI or histamine H2-receptor antagonist (e.g., 
cimetidine, famotidine) may ameliorate dyspepsia, 
which can mimic nausea [37]. Taking oral azacitidine 
with food may alleviate nausea and vomiting by dilut-
ing drug in the upper GI tract, improving motility, 
and slowing the rate of absorption [25]. The National 
Comprehensive Care Network (NCCN) guidelines for 
antiemesis recommend prophylactic use of a 5-HT3 
receptor antagonist before the start of moderately 
or highly emetogenic therapy [37]. Accordingly, the 
prescribing information for oral azacitidine recom-
mends use of anti-nausea prophylaxis before taking 
oral azacitidine for at least the first 2 treatment cycles 
[20]. Although higher-grade GI events are uncom-
mon, oral azacitidine treatment should be interrupted 
for patients who experience grade 3–4 nausea, vomit-
ing, or diarrhea, with treatment resumed once toxic-
ity resolves to grade ≤ 1. If grade 3–4 events reoccur, 
treatment should again be interrupted until resolution 
to grade ≤ 1; treatment should be resumed at a lower 
dose (200 mg/day) on second incidence, followed by a 
shorter treatment duration (reduced by 7  days) if the 
toxicity persists after dose reduction (Fig. 3) [20].
Consensus clinical practice guidelines emphasize 
use of 3 drug classes for optimal treatment of chemo-
therapy-induced nausea and vomiting: 5-HT3 receptor 
antagonists, corticosteroids, and neurokinin-1 receptor 
antagonists [28, 33, 37]. Nonpharmacologic approaches 
to reduce nausea and vomiting are shown in Additional 
file  1: Table  S2. Uncomplicated diarrhea often can be 
managed by replacement of fluids and electrolytes and 
self-administration of antidiarrheal medications (e.g., 
loperamide, lactulose, bismuth subsalicylate). If diar-
rhea is grade ≥ 3 in severity, oral azacitidine dosing 
should be interrupted until it resolves to grade ≤ 1, then 
resumed at the recommended starting dose—unless 
there is a reoccurrence, in which case a reduced dose 
(200  mg/day) and/or a reduced treatment duration 
(e.g., 7 days/cycle) should be considered.
Table 2 Most common (≥ 20%) adverse events (all grades and 
grade 3–4) in patients treated with oral azacitidine in QUAZAR 
AML‑001 [22]
Adverse events were evaluated from the date of the first dose of oral azacitidine 
or placebo through 28 days after the last dose. Preferred terms were defined 
using the Medical Dictionary of Regulatory Activities, version 22.0, and events 
were graded using the National Cancer Institute Common Terminology Criteria 
for Adverse Events, version 4.0. Patients are counted only once for multiple 




Placebo (N = 233)
All grades Grade 3–4 All grades Grade 3–4
n (%)
Patients with ≥ 1 AE 231 (98) 169 (72) 225 (97) 147 (63)
Nausea 153 (65) 6 (3) 55 (24) 1 (< 1)
Vomiting 141 (60) 7 (3) 23 (10) 0
Diarrhea 119 (50) 12 (5) 50 (21) 3 (1)
Neutropenia 105 (44) 97 (41) 61 (26) 55 (24)
Constipation 91 (39) 3 (1) 56 (24) 0
Thrombocytopenia 79 (33) 53 (22) 63 (27) 50 (21)
Fatigue 70 (30) 7 (3) 45 (19) 2 (1)
Anemia 48 (20) 33 (14) 42 (18) 30 (13)
Table 3 Maximum severity of gastrointestinal adverse events reported in > 5% of patients receiving oral azacitidine
Adverse events were evaluated from the date of the first dose of oral azacitidine or placebo through 28 days after the last dose. Preferred terms were defined using 
the Medical Dictionary of Regulatory Activities, version 22.0, and events were graded using the National Cancer Institute Common Terminology Criteria for Adverse 
Events, version 4.0. Patients are counted only once for multiple events within each preferred term
CTCAE Common Terminology Criteria for Adverse Events, GI gastrointestinal
Preferred term Total Oral azacitidine (N = 236)
Maximum CTCAE grade
1 2 3 4 5
n (%)
Any GI adverse event 215 (91) 63 (27) 118 (50) 30 (13) 4 (2) 0
Nausea 153 (65) 81 (34) 66 (28) 6 (3) 0 0
Vomiting 141 (60) 81 (34) 53 (22) 7 (3) 0 0
Diarrhea 119 (50) 62 (26) 45 (19) 11 (5) 1 (< 1) 0
Constipation 91 (39) 52 (22) 36 (15) 3 (1) 0 0
Abdominal pain 31 (13) 19 (8) 10 (4) 2 (1) 0 0
Upper abdominal pain 21 (9) 14 (6) 5 (2) 2 (1) 0 0
Flatulence 13 (6) 9 (4) 4 (2) 0 0 0







Oral-AZA, Any GI AE PBO, Any GI AE
Oral-AZA, Nausea PBO, Nausea
Oral-AZA, Vomiting PBO, Vomiting
Oral-AZA, Diarrhea PBO, Diarrhea










AE, adverse events; AZA, azacitidine; Conmeds, concomitant medications; GI, gastrointestinal; PBO, placebo.
Fig. 2 Rates of all gastrointestinal adverse events; of nausea, vomiting, and diarrhea; and use of gastrointestinal‑directed concomitant medications 
over time in the QUAZAR AML‑001 trial
Fig. 3 Recommended dosing modifications for adverse events during oral azacitidine therapy
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Hematologic events
Most treatments for hematologic malignancies have 
myelosuppressive effects [23, 38, 39]. In the QUAZAR 
AML-001 trial, hematologic AEs were reported in 66% 
of patients (155/236) in the oral azacitidine arm and 
47% (110/233) in the placebo arm. The most common 
hematologic AEs were neutropenia, thrombocytope-
nia, and anemia, which were reported for 44%, 33%, and 
20% of patients in the oral azacitidine arm, respectively, 
and in 26%, 27%, and 18% of patients in the placebo arm 
[22]. Some hematologic AEs may have been subclini-
cal, detected only because of protocol-required frequent 
laboratory monitoring during the study; for example, 
while neutropenia was reported in 44% of patients receiv-
ing oral azacitidine, febrile neutropenia occurred in only 
12% of these patients (and in 8% of patients in the pla-
cebo arm), and thrombocytopenia was reported in 33% 
of patients receiving oral azacitidine but hemorrhagic 
events were reported for 22% of patients (and in 20% of 
patients receiving placebo). Frequent monitoring also 
allowed for prompt detection of severe neutropenia or 
thrombocytopenia, and the need for oral azacitidine dos-
ing modifications.
The frequency of hematologic AEs during initial 
treatment cycles was relatively consistent in the oral 
azacitidine arm, with a downward trend in later cycles 
(Fig. 4). During cycles 1–2, 3–4, and 5–6, rates of neu-
tropenia in the oral azacitidine arm were 22%, 20%, and 
18%, respectively; of thrombocytopenia were 16%, 9%, 
and 6%; and of anemia were 6%, 4%, and 4%. Grade 3–4 
neutropenia, thrombocytopenia, and anemia occurred 
in 41%, 22%, and 14% of patients, respectively, in the 
oral azacitidine arm. Serious febrile neutropenia was 
reported for 7% of patients receiving oral azacitidine 
(placebo 4%).
While cytopenias are a known side effect of HMAs, 
they may also accompany AML relapse, and it can be 
challenging to determine whether cytopenias during 
oral azacitidine therapy are drug-related or reflect dis-
ease progression. In QUAZAR AML-001, 154 patients 
(65%) in the oral azacitidine arm and 179 (77%) in the 
placebo arm relapsed on-study. As shown in Fig.  4, 
rates of hematologic AEs decreased slightly over time 
but generally ranged from 15 to 30% in the oral azac-
itidine arm and 8–15% in the placebo arm from cycle 3 
through cycle 18, and it remains unclear how many of 
these events were potentially related to onset of AML 
relapse. In a post hoc analysis, ANC, platelet counts, 
and hemoglobin concentrations were assessed at base-
line, 30–60  days before the date of recorded relapse, 
and within 30  days of relapse (inclusive of the relapse 
date) for the 333 patients who relapsed during the 
QUAZAR AML-001 study. For comparison purposes, 
these parameters were also assessed at baseline and at 
cycles 3, 6, and 9 for non-relapsing patients. Results 
showed steep decreases in ANC and platelets (Fig.  5) 
but not hemoglobin, in the lead-up to relapse for 
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Fig. 4 Rates of all hematologic adverse events, and of neutropenia, thrombocytopenia, and anemia over time in the QUAZAR AML‑001 trial
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who did not relapse showed initial decreases in platelet 
counts and ANC, but signs of count recovery were evi-
dent after cycle 3.
Management
Clinicians should monitor blood counts during oral azac-
itidine treatment every-other week for the first 2 cycles 
and before the start of each cycle thereafter [20]. More 
frequent monitoring is also recommended for the 2 treat-
ment cycles following any dose reduction for myelosup-
pression [20].
Hematologic AEs in the oral azacitidine arm in 
QUAZAR AML-001 were primarily managed with dos-
ing modifications, including treatment interruption 
in 27% and dose reductions in 8% of patients. Only 3 
patients discontinued oral azacitidine due to a hemato-
logic AE. Oral azacitidine dosing should be delayed for 
patients with ANC < 0.5 ×  109/L at the beginning of any 
treatment cycle [20]. For patients who develop febrile 
neutropenia (ANC < 1 ×  109/L with fever) or thrombo-
cytopenia (platelets < 50 ×  109/L) during oral azacitidine 
treatment, treatment should be interrupted until count 
recovery (ANC ≥ 1 ×  109/L, platelets ≥ 50 ×  109/L). If 
multiple events of neutropenic fever or thrombocytope-
nia occur in consecutive cycles, oral azacitidine should 
again be interrupted until recovery and resumed at a 
lower dose and/or reduced schedule (Fig.  3). As part of 
prospective study design of the QUAZAR AML-001 trial, 
patients who experienced febrile neutropenia could con-
tinue receiving study drug—along with antibiotic, anti-
fungal, or antimicrobial agents—for up to 3 days before 
treatment interruption and study drug could be resumed 
no earlier than 3 days following fever resolution.
Among the 105 patients who experienced neutropenia 
during oral azacitidine treatment, 51 had oral azacitidine 
dosing interrupted [n = 47 (45%)] and/or reduced [n = 13 
(12%)], typically due to grade 3–4 events (n = 49/51). 
Myeloid growth factors, including G-CSF/filgrastim, 
were used in 50 patients (21%) in the oral azacitidine 
arm and in 36 patients (15%) in the placebo arm. Inter-
mittent G-CSF treatment may be helpful for patients 
with grade-4 neutropenia during oral azacitidine treat-
ment. Expert guidelines recommend prophylactic use of 
G-CSF when the overall risk of febrile neutropenia from 
a chemotherapy regimen is ≥ 20% of patients [27, 40]; the 
frequency of febrile neutropenia during oral azacitidine 
treatment did not meet this threshold (12%).
During oral azacitidine treatment, 23 of 79 patients 
who experienced thrombocytopenia had dosing inter-
rupted [n = 20 (25%)] and/or reduced (n = 4 [5%]), 
including 15 patients who had their dosing modified 
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Fig. 5 Changes in platelet and neutrophil counts in the lead‑up to AML relapse (and at cycles 3, 6, and 9 for patients who did not relapse) in the 
QUAZAR AML‑001 trial
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administered for 19% of patients receiving oral azaciti-
dine and 22% receiving placebo. No patient in the oral 
azacitidine arm received fibrinogen and only 1 patient 
received prothrombin on-study. NCCN clinical practice 
guidelines recommend dose modifications, platelet trans-
fusions, and use of romiplostim for patients with sub-
stantial chemotherapy-induced thrombocytopenia [31].
Supportive care measures for 48 patients in the oral 
azacitidine arm who experienced anemia included treat-
ment interruptions for 3 patients (6%) and dose reduction 
for 1 patient (2%). Rates of RBC transfusions on-study 
were similar between the oral azacitidine and placebo 
arms, in 23% and 22% of patients, respectively, and only 1 
patient received an ESA (epoetin alpha). Guidelines from 
the American Society of Clinical Oncology (ASCO) and 
the American Society of Hematology (ASH) indicate that 
ESAs may benefit patients with hemoglobin levels ≤ 10 g/
dL [41], and NCCN clinical practice guidelines for chem-
otherapy-induced anemia recommend ESAs for sympto-
matic patients with hemoglobin ≤ 11 g/dL [31].
Infections
AEs in the MedDRA System Organ Class “Infections and 
infestations” were reported for 62% of patients treated 
with oral azacitidine and 53% of patients in the placebo 
arm. Most infectious events were not considered study-
drug-related by investigators; 12% and 3% in the oral 
azacitidine and placebo arms, respectively, were consid-
ered treatment-related. The most common infections 
in the oral azacitidine arm were upper respiratory tract 
infections in 13% of patients, influenza in 8%, nasophar-
yngitis in 7% and urinary tract infections in 7%; rates of 
these events in the placebo arm were 14%, 3%, 7%, and 
6%, respectively. The prescribing information for oral 
azacitidine reports an incidence of pneumonia of 27% 
(including serious pneumonia in 8% of patients), but in 
that document, “pneumonia” encompasses a broad range 
of disorders in addition to different types of pneumonia, 
including influenza, respiratory tract infection, bron-
chopulmonary aspergillosis, lung infection, productive 
cough, and pleural effusion, among others [20]. AEs with 
the preferred term of “pneumonia” were reported in 6% 
of patients in the oral azacitidine arm and 5% of patients 
in the placebo arm, with grade 3–4 events reported for 7 
patients (3%) in each treatment arm.
Infections were the most frequent serious AEs in both 
the oral azacitidine (17%) and placebo (8%) arms. Serious 
infections in > 1 patient receiving oral azacitidine were 
pneumonia (4%), cellulitis (2%), sepsis (2%), and influenza 
(1%); these events were reported in 3% 0.4%, 2%, and 0% 
of patients in the placebo arm, respectively. Serious AEs 
were considered related to oral azacitidine treatment in 
11 patients (5%), with pneumonia (n = 6; 3%) and sepsis 
(n = 2; 1%) reported in > 1 patient. The median duration 
of serious pneumonia in the oral azacitidine arm (9 
events) was 12 days, of sepsis (4 events) was 16 days, and 
of cellulitis (4 events) was 16  days. In the placebo arm, 
median durations of serious pneumonia and sepsis (no 
cellulitis) were similar to the oral azacitidine arm (14 days 
and 16 days, respectively).
Three patients who received oral azacitidine had infec-
tions that ultimately led to death. Each of these events 
occurred in the context of AML relapse and after cessa-
tion of oral azacitidine treatment, and all 3 patients had 
received subsequent chemotherapy on or before the date 
of the infection leading to death.
Management
Overall, 13% of patients in QUAZAR AML-001 had oral 
azacitidine treatment interrupted and 1% required dose 
reductions due to infections. Treatment was discontin-
ued for 4 patients (2%) due to sepsis, pneumonia, rectal 
abscess, or lung abscess; sepsis was considered by the 
investigator to be related to oral azacitidine. The most 
common concomitant antibiotics, anti-infectives, and 
antifungal treatments during the trial were ciprofloxacin 
(22% of patients), levofloxacin (22%), and acyclovir (20%), 
which were used with similar frequencies in the placebo 
arm (16%, 19%, and 22%, respectively).
Prophylactic use of G-CSF can reduce the incidence of 
infection-related mortality in patients with cancer [27]. 
Additionally, ASCO and Infectious Diseases Society of 
America (IDSA) guidelines recommend antibacterial and 
antifungal prophylaxis for patients who are at high risk 
of infection, including patients who may be expected to 
have profound, protracted neutropenia (< 1.0 ×  109/L 
neutrophils for > 7 days) [42].
Discussion
An ideal maintenance therapy should not only prevent 
or delay relapse and prolong OS, but should also have a 
manageable safety profile that is conducive to long-term 
use. Hematologic and GI events were the most common 
AEs reported in patients who received oral azacitidine in 
the QUAZAR AML-001 trial; these events were gener-
ally manageable with dose interruptions or reductions, 
and discontinuation of oral azacitidine because of AEs 
was infrequent. Most GI AEs were low-grade, and fre-
quencies of these events decreased after initial treatment 
cycles. Because the study was blinded, use of antiemetics 
during early treatment cycles may have been infrequent, 
administered on a “wait and see” basis. GI events and use 
of concomitant GI medications decreased concurrently, 
suggesting progressive GI tolerance to oral azacitidine. 
Patient education and behavioral support can improve 
medication adherence [43], so clinicians and patients 
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should be aware of the likelihood of GI AEs during early 
oral azacitidine treatment. Prophylaxis with antiemetics 
during at least the first 2 treatment cycles, and as-needed 
symptomatic intervention, may facilitate treatment 
compliance.
Hematologic AEs were also relatively common during 
oral azacitidine treatment. Neutropenia, thrombocyto-
penia, and anemia were primarily managed with tempo-
rary treatment delays or interruptions and modifications 
to oral azacitidine dose level. Approximately one-fifth 
of patients (21%) in the oral azacitidine arm received 
a myeloid growth factor on-study. It may be prudent to 
consider prophylaxis for neutropenia during early oral 
azacitidine treatment for patients with low pretreatment 
ANC. In many cases, hematologic AEs in this trial were 
subclinical and not associated with cytopenic complica-
tions, detected only because of the required frequent 
laboratory monitoring. Some hematologic AEs in the 
oral azacitidine arm may have been associated with AML 
relapse rather than treatment-related myelosuppres-
sion; post hoc analysis of data from QUAZAR AML-001 
suggests that patients with declining ANC and platelet 
counts that do not recover after the first few treatment 
cycles may be headed toward relapse. Similar trends for 
reduced platelet and neutrophil counts within 60  days 
of relapse in the placebo arm (Fig. 5) also suggest these 
cytopenias were not entirely related to oral azacitidine 
therapy.
International consensus guidelines for supportive care 
strategies to address frequent AEs associated with cancer 
treatment have been updated, in part, to minimize hospi-
tal or clinic visits to avoid exposure to nosocomial infec-
tion [27]. Reducing the need for hospital or clinic visits 
is more convenient for patients and reduces healthcare 
resource utilization. Compared with injectable azaciti-
dine, there is no need for repeated daily clinic visits each 
month for oral azacitidine administration. Moreover, 
in a prospective analysis of hospitalization and health-
care resource utilization during the QUAZAR AML-001 
study, oral azacitidine was associated with significantly 
reduced exposure-adjusted rates of hospitalization and 
days in hospital compared with placebo [34]. Infections 
were the most common serious AEs in both treatment 
arms in QUAZAR AML-001, but did not frequently 
require dosing modifications or discontinuation.
Maintenance therapy has historically not been a com-
ponent of standard AML care because the toxicity of 
the regimens under study sometimes outweighed their 
benefits [5–7]. Therefore, it is especially important to 
consider effects of maintenance therapy on the HRQoL 
of older patients with AML in remission, as these effects 
may determine whether a patients chooses to receive 
it. HRQoL was a secondary endpoint of the QUAZAR 
AML-001 trial. Patients in both treatment arms reported 
levels of fatigue and overall HRQoL at study entry that 
were similar to those of a general population [44]. The 
relatively favorable levels of fatigue and overall HRQoL 
at study entry were preserved during oral azacitidine 
treatment, with no clinically meaningful differences in 
patient-reported HRQoL scores from baseline, or from 
scores in the placebo arm at any post-baseline visit [44].
Because oral azacitidine received regulatory approvals 
only recently, QUAZAR AML-001 currently comprises 
the most robust dataset for assessing its safety in patients 
with AML in remission. Patients in the QUAZAR AML-
001 trial may not be typical of a “general” older AML 
population, as they were eligible for and responded to 
IC, and were deemed healthy enough to participate in a 
clinical trial (but not considered fit enough for transplant 
in most cases). Additional safety information for patients 
treated with oral azacitidine outside of a clinical trial is 
anticipated.
Patients prefer oral agents, as long as efficacy is 
not compromised [45]; oral azacitidine significantly 
improved OS and RFS without diminishing HRQoL, and 
is convenient for use in the outpatient setting. Never-
theless, a concern of oral anticancer agents is ensuring 
drug adherence, which largely depends on patients’ per-
ceptions of risk/benefit/cost (including toxicity) and the 
complexity of the treatment regimen, to maximize thera-
peutic efficacy [45]. Awareness of the onset and duration 
of common AEs, and implementation of effective sup-
portive care for AE management may maximize treat-
ment adherence and optimize the survival benefits of oral 
azacitidine maintenance therapy for patients with AML 
in remission.
Conclusions
Patients who attain AML remission with IC gener-
ally begin to feel better, and despite the potential to 
obtain survival benefits with maintenance therapy, they 
may not be willing to continue receiving active treat-
ment, especially if the drug regimen confers significant 
or unexpected toxicity. It is reassuring that the gener-
ally favorable HRQoL associated with AML remission at 
entry to the QUAZAR AML-001 study was not dimin-
ished during oral azacitidine therapy. Oral azacitidine 
maintenance had a manageable safety profile, with no 
unexpected safety events in patients receiving it long-
term (> 5  years). To promote adherence to therapy, cli-
nicians should consider prophylactic use of antiemetics 
and symptomatic interventions during early oral azac-
itidine treatment to ameliorate GI events. Hematologic 
AEs during oral azacitidine therapy rarely required treat-
ment discontinuation and were mainly managed by treat-
ment delays, interruptions, or oral azacitidine dosing 
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modifications. Discerning treatment-related hematologic 
AEs from cytopenias related to relapse can be challeng-
ing; neutropenia or thrombocytopenia that does not 
show signs of improving may signal impending relapse, 
but further investigation is needed to confirm this find-
ing. Broader access to a wide range of patients with AML 
in the “real world” should further improve our under-
standing of the safety of oral azacitidine maintenance 
therapy.
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